Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress

By The Northwire Desk — AI Analysis Jan 13, 2026 · 09:00 ADK · 0.335 Diagnos Inc.
ADK · Price

Executive Summary

  • DIAGNOS submitted its AI‑based eye‑health platform CARA for marketing approval to Saudi Arabia’s SFDA.
  • The company is on track to file a formal Health Canada application for CARA within the current quarter.
  • FDA meetings clarified requirements for 510(k) clearance, positioning CARA for U.S. market entry.

Key Details

  • Saudi Arabia (SFDA): Formal submission of CARA completed; awaiting marketing approval.
  • Canada (Health Canada): Active engagement with regulator; formal application expected to be filed this quarter.
  • United States (FDA): Strategic meetings identified specific 510(k) clearance requirements; pathway cleared for subsequent submission.
  • Strategic Importance: CEO André Larente highlighted regulatory approvals as a “significant catalyst for commercial growth and shareholder value.”

Notable Quotes

“Navigating the regulatory landscape for medical AI requires precision and expertise. Our team is fully focused on meeting the rigorous standards of Canada, the U.S., and Saudi Arabia,” – André Larente, CEO
“Securing these authorizations is a priority milestone that we believe will serve as a significant catalyst for commercial growth and shareholder value.” – André Larente, CEO

Read the original news release →

More from Diagnos Inc.

Jun 18, 2026 · 12:00

Cash-preserving debt settlement underscores ongoing liquidity constraints ahead of critical CARA regulatory milestones.

Financings Jun 16, 2026 · 09:15

Pre-revenue medical AI developer navigating regulatory hurdles while burning through cash reserves.

Regulatory Jun 05, 2026 · 10:00

DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

Regulatory Apr 08, 2026 · 12:14

Regulatory timeline update keeps CARA on track, no surprise for investors

Production / Operations Mar 05, 2026 · 18:26

Diagnos to amend convertible debenture, warrant terms

Financings Mar 05, 2026 · 15:45

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

Financings